Market Access News | pharmaphorum

News

A male HCP discusses treatment with an older male patient

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

News

ICER says US new drug launch prices have risen sharply

ICER says the prices of new drug launches in the US rose 51% in three years, adding up to $1.5bn in first-year costs to US health systems.

News

GSK's Blenrep's back in US, but with a narrower label

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale.

News

CHMP backs first drug for lung disease bronchiectasis

Insmed gets EU recommendation for first non-cystic fibrosis bronchiectasis therapy Brinsupri, plus other CHMP decisions.

News

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.

News

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.

Bayer's prostate cancer drug Nubeqa cleared for NHS use

ICER says US new drug launch prices have risen sharply

GSK's Blenrep's back in US, but with a narrower label

CHMP backs first drug for lung disease bronchiectasis

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

News

Editor's Picks